Danicopan not checked
Alexion Pharmaceuticals, Inc. · ALXN2040 · ACH-4471
FollowEvery change as it happens, and a Monday email
Trials
2 active
26 in total · 4 in the EU
What this is
- How it works
- Complement Factor D Inhibitor FDA class
- How it’s given
- “Participants will receive danicopan on a weight-based dosing regimen.”In the company’s words, NCT06449001 on ClinicalTrials.gov
- Tested for
- Paroxysmal Nocturnal Hemoglobinuria (2 trials), PNH, Extravascular Hemolysis
- Main trialPhase 3
- “This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.”In the company’s words, NCT05389449 on ClinicalTrials.gov
- Other names
- ALXN2040 · ACH-4471 · 4471 · ACH-0144471
Other drugs for Paroxysmal Nocturnal Hemoglobinuria
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- CrovalimabRoche · Phase 3
- VSA012Bisirna Therapeutics (Suzhou) Co., Ltd. · Phase 3
- IptacopanNovartis Pharmaceuticals · Phase 3
- FXS6837Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase 3
Coming up1
- 28 May 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials26
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 24 Aug 2026 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | |
| Phase 3Recruiting | 28 May 2027 | Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis | |
| Phase 3Completed | 29 Jun 2022 | Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) | |
| Phase 2Completed | 14 Nov 2018 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | |
| Phase 2Completed | 21 Dec 2018 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN | |
| Phase 2Completed | 20 Sep 2019 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab | |
| Phase 2Completed | 11 Dec 2019 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) | |
| Phase 2Terminated | 29 Mar 2021 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 | |
| Phase 2Completed | 4 Jan 2022 | A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | |
| Phase 2Terminated | 5 Jul 2024 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | |
| Phase 1Completed | 21 Jun 2016 | Study of a Single Dose of Danicopan in Healthy Participants | |
| Phase 1Completed | 5 Oct 2016 | Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants | |
| Phase 1Completed | 11 Jan 2017 | Study of Multiple Doses of Danicopan in Healthy Participants | |
| Phase 1Completed | 2 Jun 2017 | A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants | |
| Phase 1Completed | 15 Oct 2017 | Study of Radiolabeled Danicopan in Healthy Male Participants | |
| Phase 1Completed | 21 Mar 2018 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | |
| Phase 1Completed | 29 May 2018 | Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction | |
| Phase 1Completed | 21 Sep 2018 | Study of Danicopan in Participants With Hepatic Impairment | |
| Phase 1Completed | 12 Oct 2018 | A Study of the Cardiac Effects of Danicopan in Healthy Adults | |
| Phase 1Completed | 17 Oct 2018 | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults | |
| Phase 1Completed | 14 Oct 2019 | A Drug Interaction Study of Danicopan | |
| Phase 1Completed | 28 Sep 2020 | Study of Danicopan in Participants of Japanese Descent | |
| Phase 1Completed | 7 Dec 2020 | Study of the Metabolism of Danicopan in Healthy Adults | |
| Phase 1Completed | 3 Feb 2021 | A Study of the Effects of Food and Age on Danicopan | |
| Phase 1Completed | 23 Mar 2023 | Potential Drug Interaction Between ALXN2040 and Rosuvastatin | |
| Phase 2Ended | not given | Proof of concept study to assess the efficacy and safety of Danicopan (factor D inhibitor) in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment (DANICSU). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026